Biotech

All Articles

Actinogen's cortisol blocker falls short phase 2 depression research

.Actinogen Medical's cortisol blocker has missed the key endpoint of a stage 2 research study in dep...

Bivictrix determines going personal only means to take ADC right into facility

.Antibody-drug conjugates (ADCs) have been at the facility of several a billion-dollar biobuck licen...

TPG tops up funds to $580M for assets throughout life sciences

.Property supervisor TPG, which has actually sustained biotechs such as Sionna Therapeutics as well ...

Merck ceases period 3 TIGIT trial in bronchi cancer for futility

.Merck &amp Co.'s TIGIT system has gone through an additional setback. Months after shuttering a per...

After a challenging year, Exscientia folds up in to Recursion

.After a year defined by pipe cuts, the departure of its chief executive officer as well as cutbacks...

Cullinan, after $25M offer, restore bispecific to Harbour

.Cullinan Therapeutics was impressed good enough along with Harbour BioMed's bispecific immune syste...

A better look at Intense Biotech's Tough 15

.Within this week's incident of "The Best Line," our team're diving into Intense Biotech's yearly In...

Lilly encounters phase 2 breakdown of tau-targeting med

.The confetti is actually still soaring from Eli Lilly's party celebrating the approval of Alzheimer...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of notable leadership hirings, shootings and al...

Lykos will definitely talk to FDA to reassess its own decision following turndown of MDMA therapy for post-traumatic stress disorder

.Adhering to a bad presenting for Lykos Rehabs' MDMA applicant for post-traumatic stress disorder at...